• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

有糖尿病与无糖尿病患者减肥干预措施的疗效差异

Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes.

作者信息

Losada-Díaz Federico, Lizarazo-Bocanegra Santiago, Perdomo-Lugo Juan J, Gutiérrez-Romero Sebastián A, Correa-Osio Isabella, Mendivil Carlos O

机构信息

School of Medicine, Universidad de los Andes, Bogotá, Colombia.

Section of Endocrinology, Department of Internal Medicine, Fundación Santa Fe de Bogotá, Bogotá, Colombia.

出版信息

Diabetes Ther. 2024 Nov;15(11):2279-2291. doi: 10.1007/s13300-024-01646-y. Epub 2024 Sep 14.

DOI:10.1007/s13300-024-01646-y
PMID:39276293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11467141/
Abstract

Obesity is both a major risk factor for diabetes and a serious comorbidity of the condition. The twin epidemics of obesity and diabetes have spread globally over the past few decades. Treatment of obesity in patients with diabetes provides a host of clinical benefits that encompass virtually all body systems. Despite this, multiple lines of evidence suggest that the efficacy of most therapies for weight loss is significantly reduced among patients with diabetes. With this background, we summarize the evidence of a differential effect of lifestyle, pharmacological, and surgical treatments for obesity in patients with existing diabetes, and explore the potential mechanisms involved in this phenomenon. This information is then used to formulate strategies to improve weight loss outcomes for patients with diabetes.

摘要

肥胖既是糖尿病的主要危险因素，也是该疾病的严重合并症。在过去几十年中，肥胖和糖尿病这两大流行疾病已在全球蔓延。糖尿病患者的肥胖治疗带来了一系列临床益处，几乎涵盖所有身体系统。尽管如此，多项证据表明，对于糖尿病患者，大多数减肥疗法的疗效会显著降低。在此背景下，我们总结了生活方式、药物和手术治疗对现有糖尿病患者肥胖的不同影响的证据，并探讨了这一现象背后的潜在机制。然后利用这些信息制定策略，以改善糖尿病患者的减肥效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/30ef41c94e04/13300_2024_1646_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/6e606b4a4cba/13300_2024_1646_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/9b66ff9c0d01/13300_2024_1646_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/b13eb182b94a/13300_2024_1646_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/30ef41c94e04/13300_2024_1646_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/6e606b4a4cba/13300_2024_1646_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/9b66ff9c0d01/13300_2024_1646_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/b13eb182b94a/13300_2024_1646_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ab9/11467141/30ef41c94e04/13300_2024_1646_Fig4_HTML.jpg

相似文献

1
Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes.有糖尿病与无糖尿病患者减肥干预措施的疗效差异
Diabetes Ther. 2024 Nov;15(11):2279-2291. doi: 10.1007/s13300-024-01646-y. Epub 2024 Sep 14.
2
Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs.当代肥胖症管理：减重代谢手术与新型肠促胰岛素类似物药物的比较。
Diabetes Technol Ther. 2024 Sep;26(9):673-685. doi: 10.1089/dia.2024.0122. Epub 2024 May 16.
3
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.GLP-1 受体激动剂作用机制与体重减轻和维持的关系。
Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11.
4
The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.减肥手术治疗肥胖症的临床疗效和成本效益：一项系统评价与经济评估
Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410.
5
Obesity Management in Adults: A Review.成人肥胖管理：综述。
JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897.
6
Pharmacotherapy before and after bariatric surgery.减肥手术前后的药物治疗。
Metabolism. 2023 Nov;148:155692. doi: 10.1016/j.metabol.2023.155692. Epub 2023 Sep 18.
7
Bariatric surgery: an evidence-based analysis.减重手术：一项基于证据的分析。
Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 1.
8
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.肥胖的医学和手术治疗方法对代谢组学、脂质和脂蛋白的早期变化的影响。
Metabolism. 2023 Jan;138:155346. doi: 10.1016/j.metabol.2022.155346. Epub 2022 Nov 12.
9
Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.GLP-1 受体激动剂和减重手术的使用对肥胖政策的支持。
Ann Behav Med. 2024 Nov 16;58(12):857-862. doi: 10.1093/abm/kaae063.
10
Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment.成人 I 级肥胖伴难以控制 2 型糖尿病患者的减重手术：一项卫生技术评估。
Ont Health Technol Assess Ser. 2023 Dec 5;23(8):1-151. eCollection 2023.

引用本文的文献

1
Retrograde evoked compound action potentials as an alternative for close-loop spinal cord stimulation.逆行诱发复合动作电位作为闭环脊髓刺激的替代方法。
Sci Rep. 2024 Dec 3;14(1):30141. doi: 10.1038/s41598-024-81775-3.

本文引用的文献

1
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.司美格鲁肽在超重和肥胖 1 型糖尿病患者中的疗效。
Diabetes Technol Ther. 2024 Mar;26(3):184-189. doi: 10.1089/dia.2023.0490.
2
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.全球范围内 1990 年至 2022 年体重不足和肥胖趋势：对 3663 项具有 2.22 亿儿童、青少年和成年人代表性的人群研究进行的汇总分析。
Lancet. 2024 Mar 16;403(10431):1027-1050. doi: 10.1016/S0140-6736(23)02750-2. Epub 2024 Feb 29.
3
Hypothalamic AMP-Activated Protein Kinase as a Whole-Body Energy Sensor and Regulator.
下丘脑 AMP 激活蛋白激酶作为全身能量传感器和调节剂。
Endocrinol Metab (Seoul). 2024 Feb;39(1):1-11. doi: 10.3803/EnM.2024.1922. Epub 2024 Feb 14.
4
Outcomes and Adverse Events After Bariatric Surgery: An Updated Systematic Review and Meta-analysis, 2013-2023.减肥手术后的结局与不良事件：2013 - 2023年最新系统评价与荟萃分析
J Metab Bariatr Surg. 2023 Dec;12(2):76-88. doi: 10.17476/jmbs.2023.12.2.76. Epub 2023 Dec 28.
5
The emergence of obesity in type 1 diabetes.1 型糖尿病患者中肥胖症的出现。
Int J Obes (Lond). 2024 Mar;48(3):289-301. doi: 10.1038/s41366-023-01429-8. Epub 2023 Dec 14.
6
The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.皮下注射度拉糖肽对 2 型糖尿病患者体重减轻的影响：随机对照试验的系统评价和荟萃分析。
Eur J Clin Invest. 2024 Apr;54(4):e14125. doi: 10.1111/eci.14125. Epub 2023 Nov 11.
7
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.超重或肥胖成年人强化生活方式干预后使用替尔泊肽：SURMOUNT-3 期临床试验。
Nat Med. 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15.
8
Cognitive behavioral therapy for lifestyle changes in patients with obesity and type 2 diabetes: a systematic review and meta-analysis.认知行为疗法在肥胖合并 2 型糖尿病患者生活方式改变中的应用：系统评价和荟萃分析。
Sci Rep. 2023 Aug 7;13(1):12793. doi: 10.1038/s41598-023-40141-5.
9
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments.肥胖与 2 型糖尿病：流行病学、发病机制和治疗中的关联。
Front Endocrinol (Lausanne). 2023 Apr 21;14:1161521. doi: 10.3389/fendo.2023.1161521. eCollection 2023.
10
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.口服司美格鲁肽治疗2型糖尿病的疗效与安全性：一项系统评价与荟萃分析。
Diabetes Res Clin Pract. 2023 Apr;198:110605. doi: 10.1016/j.diabres.2023.110605. Epub 2023 Mar 5.